Thieler Law Corp advises investors with losses exceeding $100,000 of the May 11, 2020 lead plaintiff deadline in a class action lawsuit filed against Inovio Pharmaceuticals, Inc. (NASDAQ: INO) (“Inovio” or “the Company”). The suit is pending in the U.S. District Court for the Eastern District of Pennsylvania and investors, who purchased Inovio Pharmaceuticals Inc securities between February 14, 2020 and March 9, 2020, have until May 11, 2020 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Inovio Pharmaceuticals Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

According to the Complaint, the Company throughout the Class Period made false and/or misleading statements about the company’s development of a purported vaccine for the novel coronavirus, artificially inflating the company’s share price and resulting in significant investor losses.

On February 14, 2020, the Company, revealed that it could “rapidly construct” a vaccine to COVID-19 “in a matter of about three hours once we had the DNA sequence from the virus available because of the power of our DNA medicine platform.” 

On March 3, 2020, the Company revealed an accelerated timeline for developing its DNA vaccine. 

On March 9, 2020, financial analyst Citron Research published an announcement on Twitter that the “SEC should immediately halt [the Company] stock and investigate the ludicrous and dangerous claim that they designed a vaccine in 3 hours. This has been a serial stock promotion for years.  This will trade back to $2.”

Following this news, the price of the Company shares declined precipitously, from a high of $19.36 per share on March 9, 2020, to a close of $5.70 on March 10, 2020.

If you were negatively impacted by your investment in Inovio Pharmaceuticals Inc securities between February 14, 2020 and March 9, 2020 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185